How does the presence of lymphangitic spread in a single lobe impact your management strategy for locally advanced NSCLC?

in my anecdote of n=1 I included the entire lobe as CTV/ITV - chemoRT 60/30 followed by durva. Provided lung constraints are met I would suggest to include entire lobe as is at risk